Last updated: June 30, 2022
Sponsor: Universitaire Ziekenhuizen Leuven
Overall Status: Active - Recruiting
Phase
4
Condition
N/ATreatment
N/AClinical Study ID
NCT05432843
S52107
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 18-80 years
- Globus symptoms for more than three months
- First symptoms > 6 months ago
- Signed informed consent
Exclusion
Exclusion Criteria:
- Gabapentin/pregabalin treatment
- Unstable neuroleptic or antidepressive treatment (stable dose during min 8 weeks)
- Symptom relief under PPI treatment (min 8 weeks full dose)
- Patients with persisting esophagitis of Los Angeles grade B or higher under PPI onupper GI endoscopy
- Primary esophageal motility disorder (achalasia, scleroderma, dermatomyositis, …)
- Eosinophilic esophagitis
- Candida esophagitis
- Mechanical explanation of symptoms (e.g. stricture in the pharyngo-esophageal region)
- Pregnancy or plans for pregnancy in the next 12 months (in females)
- History of previous resective gastric or esophageal surgery, cervical spine fusion,Zenker's diverticulum, esophageal epiphrenic diverticulum,
Study Design
Total Participants: 90
Study Start date:
March 12, 2010
Estimated Completion Date:
January 31, 2023
Study Description
Connect with a study center
University Hospital Leuven
Leuven, België 3000
BelgiumActive - Recruiting
Annelies Geeraerts
Leuven, 3000
BelgiumActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.